Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ALVOW
Upturn stock ratingUpturn stock rating

Alvotech Warrant (ALVOW)

Upturn stock ratingUpturn stock rating
$1.7
Last Close (24-hour delay)
Profit since last BUY-17.07%
upturn advisory
WEAK BUY
BUY since 20 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/26/2025: ALVOW (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $

1 Year Target Price $

Analysts Price Target For last 52 week
$Target price
Low$
Current$1.7
high$

Analysis of Past Performance

Type Stock
Historic Profit 33.63%
Avg. Invested days 37
Today’s Advisory WEAK BUY
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/26/2025

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta 0.19
52 Weeks Range 1.02 - 4.99
Updated Date 05/16/2025
52 Weeks Range 1.02 - 4.99
Updated Date 05/16/2025
Dividends yield (FY) -
Basic EPS (TTM) -

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 16.42%
Operating Margin (TTM) 7.97%

Management Effectiveness

Return on Assets (TTM) 7.02%
Return on Equity (TTM) -

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 100126591
Shares Outstanding -
Shares Floating 100126591
Percent Insiders -
Percent Institutions -

Analyst Ratings

Rating -
Target Price -
Buy -
Strong Buy -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Alvotech Warrant

stock logo

Company Overview

overview logo History and Background

Alvotech is a biopharmaceutical company focused on the development and manufacture of biosimilar medicines. The warrant provides the holder the right to purchase shares of Alvotech common stock under specific terms.

business area logo Core Business Areas

  • Biosimilar Development: Alvotech focuses on developing biosimilars for a range of therapeutic areas, targeting complex molecules and high-value biological products.
  • Manufacturing: The company has advanced manufacturing capabilities for producing biosimilars at scale.
  • Commercialization: Alvotech partners with other pharmaceutical companies to commercialize its biosimilars globally.

leadership logo Leadership and Structure

Alvotech is led by a team with experience in biosimilar development, manufacturing, and commercialization. The organizational structure includes departments for research and development, manufacturing, quality control, and commercial operations.

Top Products and Market Share

overview logo Key Offerings

  • AVT02 (adalimumab biosimilar): A biosimilar of Humira (adalimumab) used to treat autoimmune diseases. Competitors include Amgen (Amjevita), Sandoz (Hyrimoz), and other adalimumab biosimilars. Market share data is variable depending on region and launch timing but this is a lead product. Revenue from AVT02 is a significant portion of Alvotech's total revenue, though specific figures are proprietary.
  • AVT04 (ustekinumab biosimilar): A biosimilar of Stelara (ustekinumab) used to treat psoriasis, Crohn's disease, and ulcerative colitis. Competitors will include biosimilars developed by other pharmaceutical companies such as Biocon and possibly Amgen. Market share will depend on launch timing and regulatory approvals. Currently in development.

Market Dynamics

industry overview logo Industry Overview

The biosimilar market is growing rapidly as patents on many blockbuster biologics expire. This creates opportunities for companies like Alvotech to develop and commercialize more affordable versions of these drugs.

Positioning

Alvotech is positioned as a key player in the biosimilar market with a focus on complex molecules and a global commercialization strategy. Its competitive advantage lies in its manufacturing capabilities and partnerships with established pharmaceutical companies.

Total Addressable Market (TAM)

The global biosimilars market is expected to reach hundreds of billions of dollars by the end of the decade. Alvotech is positioned to capture a significant share of this market with its portfolio of biosimilars targeting high-value biologics. TAM estimates range from $400-$700 billion by 2030.

Upturn SWOT Analysis

Strengths

  • Strong pipeline of biosimilar candidates
  • Advanced manufacturing capabilities
  • Strategic partnerships for commercialization
  • Focus on complex molecules

Weaknesses

  • Reliance on partnerships for commercialization
  • Regulatory hurdles for biosimilar approvals
  • Intense competition in the biosimilar market
  • Relatively smaller size compared to major pharmaceutical companies

Opportunities

  • Expanding biosimilar market globally
  • Patent expirations of blockbuster biologics
  • Growing demand for affordable medicines
  • Potential for new partnerships and collaborations

Threats

  • Regulatory challenges and delays
  • Price erosion due to competition
  • Patent litigation from originator companies
  • Biosimilar adoption barriers

Competitors and Market Share

competitor logo Key Competitors

  • AMGN
  • PFE
  • VTRS

Competitive Landscape

Alvotech's competitiveness hinges on its biosimilar pipeline, manufacturing efficiency, and market access strategies against larger, more established pharmaceutical companies.

Growth Trajectory and Initiatives

Historical Growth: Historical growth depends on past performance metrics, as well as successful biosimilar commercialization.

Future Projections: Future projections would depend on successful drug approvals and partnerships.

Recent Initiatives: Recent initiatives include new partnerships and commercialization agreements.

Summary

Alvotech warrants are inherently speculative because they are only valuable if Alvotech's stock rises above the strike price before the warrant expires. Success depends on successful drug development, regulatory approvals, and commercialization partnerships. The biosimilar market is competitive, and Alvotech faces threats from larger pharmaceutical companies and potential delays. However, the warrants offer potential for high returns if Alvotech can successfully execute its growth strategy.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • SEC filings
  • Company press releases
  • Industry reports
  • Analyst reports

Disclaimers:

The data and analysis provided are for informational purposes only and should not be considered financial advice. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor. Market share data is estimated and may vary.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Alvotech Warrant

Exchange NASDAQ
Headquaters -
IPO Launch date 2022-06-16
CEO, Founder & Executive Chairman Mr. Robert Wessman
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Full time employees 1012
Full time employees 1012

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.